High-Grade Glioma – Pipeline Review, H2 2019
- Pages: 568
- Published: December 2019
- Report Code: GMDHC11738IDB
Global Markets Direct’s, ‘High-Grade Glioma – Pipeline Review, H2 2019’, provides an overview of the High-Grade Glioma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma
– The report reviews pipeline therapeutics for High-Grade Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved High-Grade Glioma therapeutics and enlists all their major and minor projects
– The report assesses High-Grade Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for High-Grade Glioma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Aadi Bioscience Inc
Advanz Pharmaceutical Corp
Advenchen Laboratories LLC
AngioChem Inc
Apollomics Inc
Athenex Inc
Bayer AG
BeiGene Ltd
Berg LLC
Bio-Cancer Treatment International Ltd
Biomimetix JV LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Curis Inc
Curtana Pharmaceuticals Inc
DNAtrix Inc
Eisai Co Ltd
EpicentRx Inc
Erimos Pharmaceuticals LLC
Everfront Biotech Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Genor BioPharma Co Ltd
GtreeBNT Co Ltd
Hanmi Pharmaceuticals Co Ltd
Ipsen SA
Karyopharm Therapeutics Inc
Mana Therapeutics Inc
Millennium Pharmaceuticals Inc
MimiVax LLC
NewLink Genetics Corp
Northwest Biotherapeutics Inc
Novartis AG
Oncoceutics Inc
Oncotelic Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Prelude Therapeutics Inc
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Targepeutics Inc
Tessa Therapeutics Pte Ltd
TheraBiologics Inc
TVAX Biomedical Inc
ZIOPHARM Oncology Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.